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ABSTRACT
Sickle cell disease affects more than 100,000 individuals in the United 
States, among whom disease severity varies considerably.  One factor that 
influences disease severity is the sickle cell disease genotype.  For this reason, 
clinical prevention and treatment guidelines tend to differentiate between 
genotypes.  However, previous research suggests caution when using a claims-
based determination of sickle cell disease genotype in healthcare quality 
studies.
The objective of this study was to describe the extent of miscoding for 
the major sickle cell disease genotypes in hospital discharge data.  Individuals 
with sickle cell disease were identified through newborn screening results 
or hemoglobinopathy specialty care centers, along with their sickle cell 
disease genotypes.  These genotypes were compared to the diagnosis codes 
listed in hospital discharge data to assess the accuracy of the hospital codes 
in determining sickle cell disease genotype. Eighty-three percent (sickle cell 
anemia), 23% (Hemoglobin SC), and 31% (Hemoglobin Sβ+ thalassemia) 
of hospitalizations contained a diagnosis code that correctly reflected the 
individual’s true sickle cell disease genotype.  The accuracy of the sickle 
cell disease genotype coding was indeterminate in 11% (sickle cell anemia), 
12% (Hemoglobin SC), and 7% (Hemoglobin Sβ+ thalassemia) and incorrect 
in 3% (sickle cell anemia), 61% (Hemoglobin SC), and 52% (Hemoglobin Sβ+ 
thalassemia) of the hospitalizations.  The use of ICD-9-CM codes from hospital 
discharge data for determining specific sickle cell disease genotypes is 
problematic.  Research based solely on these or other types of administrative 
data could lead to incorrect understanding of the disease.
Background
Sickle cell disease (SCD) is characterized by chronic hemolytic 
anemia and a wide variety of acute and chronic complications 
caused by intermittent episodes of vaso-occlusion, vascular injury, 
and organ damage. SCD affects more than 100,000 individuals in the 
United States1 and with recent advances in care, individuals with 
SCD are living longer2.  Even so, disease severity varies considerably 
among individuals.  While some exhibit severe complications and 
die before reaching middle age, others are far less symptomatic3. 
One factor that influences disease severity is the SCD genotype. 
In the United States, most individuals with SCD have homozygous 
hemoglobin (Hb) SS disease (Hb SS), and the remainder have a 
compound heterozygous form of SCD caused by co-inheritance of 
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Hb S with a different beta globin mutation such as Hb C or a 
variety of β thalassemia mutations4.  The Hb Sβ thalassemias 
are divided into two groups depending on the severity of 
the β thalassemia mutation; mutations that result in absent 
production of β globin are termed Hb Sβ0 thalassemia while 
those that result in reduced, but not absent, production of 
β globin are termed Hb Sβ+ thalassemia.  Individuals with 
Hb SS or Hb Sβ0 thalassemia are classified as having sickle 
cell anemia (SCA) because their hematological phenotype 
is characterized by a more severe chronic hemolytic 
anemia than those with Hb SC or Hb Sβ+ thalassemia, 
who have less hemolysis and less severe or no anemia. 
In the United States, Hb SC is the most prevalent of the 
compound heterozygous SCD genotypes, followed by Hb 
Sβ+ thalassemia and then Hb Sβ0 thalassemia.    A recent 
population-based surveillance study from six states found 
that 61.4% of individuals with SCD had SCA, 28.3% had Hb 
SC, 8.5% had Hb Sβ+ thalassemia, and 1.8% had another 
compound heterozygous form of SCD5.   
It is sometimes difficult to distinguish between the two 
SCA genotypes because the co-inheritance of α thalassemia 
in persons with Hb SS results in significant overlap of 
complete blood count and hemoglobin electrophoresis 
results in persons with Hb Sβ0 thalassemia. Therefore, the 
genotypes cannot be reliably differentiated without DNA 
analysis. However, the distinction between SCA and Hb SC/
Hb Sβ+ thalassemia is important because the risk for some 
of the more severe complications of SCD, such as stroke, 
is much higher in SCA than in Hb SC/Hb Sβ+ thalassemia, 
especially during childhood6.  For this reason, clinical 
prevention and treatment guidelines tend to differentiate 
between genotypes in their practice recommendations 
based on evidence of clinical effectiveness and differing 
risk- benefit trade-offs. For example, annual transcranial 
Doppler screening for prevention of stroke in childhood is 
recommended for children with SCA but not for those with 
Hb SC or Hb Sβ+ thalassemia. Similarly, indications for use 
of hydroxyurea are much broader and more inclusive for 
SCA compared to Hb SC or Hb Sβ+ thalassemia7. 
International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes have 
been commonly used by public health officials and health 
services researchers to identify individuals with SCD to 
evaluate complications, adherence to treatment guidelines, 
and the quality of care received.  Because researchers have 
questioned the accuracy of SCD genotypes based on ICD-9-
CM codes8,9, studies usually identify patients based on any 
SCD code (282.41-42, 282.6, 282.60-64, 282.68-69) in any 
position, primary, secondary or other10-13.  A few of these 
studies have reported results by genotype, including reports 
detailing rehospitalizations14, influenza15, stroke16, and 
surgical outcomes for individuals with SCD17.  Furthermore, 
some studies have been restricted to individuals with 
Hb SS codes only18-20 and others were limited to only 
individuals with ICD-9-CM codes for SCD crisis21-24.  In only 
one instance has the accuracy of coding by SCD genotype 
been reported25. In that report, findings from an analysis of 
emergency department visits at a children’s hospital found 
that ICD-9-CM codes for Hb SS were 87% accurate, but the 
Hb SS codes were very often used for ED visits of patients 
with other genotypes.  Therefore, the authors suggested 
caution when using a claims-based determination of SCD 
genotype in healthcare quality studies.
Georgia and California have a unique set of SCD 
surveillance data collected through the Registry and 
Surveillance System for Hemoglobinopathies (RuSH)5. 
These population-based data can be used to test the 
accuracy of hospital discharge data for identifying SCD 
genotypes and, in turn, their utility in evaluating adherence 
to practice recommendations that differ by genotype.  This 
is possible by comparing ICD-9-CM codes  from the hospital 
discharge data to laboratory-based information collected 
from clinical sites and state newborn screening programs 
within the RuSH surveillance datasets.  The purpose of 
this study was to use the hospital discharge records of a 
population-based sample to (1) describe the extent of 
miscoding for the major SCD genotypes and estimate the 
accuracy of ICD-9-CM codes and (2) report the positive 
predictive value of using Hb SS ICD-9-CM codes only 
(282.61 and 282.62) to identify individuals with SCA. 
Methods
The methods that California and Georgia used to collect 
and link population-based SCD surveillance data for 2004 to 
2008 from a variety of sources were previously described5. 
The analyses presented here include individuals with SCD 
who were reported by newborn screening and/or one of 
the participating hemoglobinopathy specialty treatment 
centers (Georgia: Georgia Comprehensive Sickle Cell Center 
at Grady Memorial, Georgia Health Sciences University, and 
all three campuses of Children’s Healthcare of Atlanta; 
California: University of California (UC) San Francisco 
Benioff Children’s Hospital Oakland and San Francisco, 
Children’s Hospital Los Angeles, UC Irvine Medical 
Center, Rady UC San Diego, UC Davis Medical Center) 
with a laboratory-confirmed diagnosis based on results of 
clinical laboratory evaluation that included quantitative 
hemoglobin identification by hemoglobin  electrophoresis, 
high-performance liquid chromatography or DNA analysis. 
These individuals were then linked to inpatient files from 
each state’s hospital discharge data (all records from 2004 
to 2008) using multiple patient identifiers.  This study only 
included individuals who had at least one hospitalization 
reported during the five year period. 
The hospital discharge data from Georgia included 
a maximum of ten diagnosis codes per admission; in 
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from further analyses (n=78  California; n=68 Georgia). 
Admissions that included more than one SCD related ICD-
9-CM diagnosis code were also removed (n=18 California, 
n=119 Georgia).  The data analysis for this study was 
generated using SAS® version 9.3 (SAS Institute, 2010).
Results
The RuSH surveillance project identified a total 
of 6,264 individuals with a known SCD genotype in 
California and Georgia; 1,976 in California and 4,288 in 
Georgia.  Of these, 3,961 (63.2%) accounted for a total of 
27,439 hospitalizations during 2004 through 2008 (Table 
1); 43.2% were for pediatric patients aged 18 years or 
younger at the time of admission, and 46.8% were male 
patients.  Individuals with SCA accounted for 72.5% of the 
patients with a known genotype and 79.9% of the hospital 
discharges; Hb SC accounted for 21.4% of patients and 
15.3% of discharges; Hb Sβ+ thalassemia accounted for 
5.5% of patients and 4.2% of discharges.
ICD-9-CM coding correctly identified SCA genotypes 
in 82.9% of hospitalizations (78.9% in CA, 84.5% in GA), 
the California data there were up to 25 diagnosis codes 
per admission.  All of the diagnosis codes were scanned 
for the presence of an SCD ICD-9-CM code.  These SCD 
codes were then compared to the known SCD genotype 
for the individual, and a determination of “correct,” 
“indeterminate,” “incorrect,” or “no code” was made, based 
on whether or not the diagnosis code and the known SCD 
genotype were considered to be a correct match (Figure 1). 
These categorizations were defined from the perspective 
of the known SCD genotype. That is, for a hospitalization of 
an individual with SCA, the “sickle-cell thalassemia with/
without crisis” (282.41, 282.42) ICD-9-CM codes would 
be “correct” if the individual had Hb Sβ0 thalassemia, but 
incorrect if the individual had Hb SS, so the comparison 
was termed “indeterminate.”  On the other hand, a 
hospitalization of an individual with Hb Sβ+ thalassemia 
would be termed “correct,” if the same codes were listed.  
Hospital admissions for individuals with SCD genotypes 
other than Hb SS/Hb Sβ0 thalassemia, Hb SC,  or Hb Sβ+ 
thalassemia are provided in Table 1, but were excluded 
Figure 1: Comparison of known sickle cell disease (SCD) genotype and SCD ICD-9-CM hospital discharge code, California and Georgia, 
2004-2008.
  Sickle cell disease genotype 
ICD-9-CM Code Sickle cell anemia Hb SC 
Hb Sβ+ 
thalassemia 
282.41: Sickle-cell thalassemia without crisis       
282.42: Sickle-cell thalassemia with crisis       
282.6: Sickle-cell disease       
282.60: Sickle-cell disease, unspecified       
282.61: Hemoglobin-SS disease without crisis       
282.62: Hemoglobin-SS disease with crisis       
282.63: Sickle-cell/hemoglobin-C disease without 
crisis       
282.64: Sickle-cell/hemoglobin-C disease with 
crisis       
282.68: Other sickle-cell disease without crisis       
282.69: Other sickle-cell disease with crisis       
 Correct = dots; indeterminate = horizontal lines; incorrect = crosshatch
Table 1: Description of patients with sickle cell disease and their hospital admissions, California and Georgia, 2004-2008.
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Figure 2a: Accuracy of ICD-9-CM hospital discharge codes for determining sickle cell disease genotype, California, 2004-2008.
 
 Sickle cell anemia Hb SC Hb Sb+ thalassemia
 0-18 years 19+ years 0-18 years 19+ years 0-18 years 19+ years
 n=3177 n=3012 n=501 n=772 n=189 n=85
ICD code is correct 2448 (77%) 2434 (81%) 211 (42%) 100 (13%) 116 (61%) 38 (45%)
ICD code is indeterminant 532 (17%) 423 (14%) 49 (10%) 53 (7%) 11 (6%) 7 (8%)
ICD code is incorrect 171 (5%) 107 (4%) 224 (45%) 597 (77%) 38 (20%) 34 (40%)
No SCD ICD code 26 (1%) 48 (2%) 17 (3%) 22 (3%) 24 (13%) 6 (7%)
0%
20%
40%
60%
80%
100%
California
SCD ICD code is correct SCD ICD code is indeterminant
SCD ICD code is incorrect No SCD ICD code
Figure 2b: Accuracy of ICD-9-CM hospital discharge codes for determining sickle cell disease genotype, Georgia, 2004-2008.
 
 Sickle cell anemia Hb SC Hb Sb+ thalassemia 
 0-18 years 19+ years 0-18 years 19+ years 0-18 years 19+ years
 n=6529 n=9113 n=1140 n=1782 n=204 n=671 
ICD code is correct 5302 (81%) 7918 (87%) 577 (51%) 69 (4%) 102 (50%) 94 (14%) 
ICD code is indeterminant 703 (11%) 822 (9%) 134 (12%) 248 (14%) 6 (3%) 57 (8%) 
ICD code is incorrect 180 (3%) 281 (3%) 328 (29%) 1406 (79%) 53 (26%) 475 (71%)
No SCD ICD code 344 (5%) 92 (1%) 101 (9%) 59 (3%) 43 (21%) 45 (7%) 
0%
20%
40%
60%
80%
100%
Georgia
SCD ICD code is correct SCD ICD code is indeterminant
SCD ICD code is incorrect No SCD ICD code
while the coding was incorrect in 3.4% (4.5% in CA, 2.9% 
in GA) and indeterminate in 11.4% (15.4% in CA, 9.7% in 
GA).  However, coding for Hb SC was correct in only 22.8% 
(24.4% in CA, 22.1% in GA) of hospitalizations, incorrect 
in 60.9% (64.5% in CA, 59.3% in GA) and indeterminate 
in 11.5% (8.0% CA, 13.1% GA). Individuals with Hb 
Sβ+ thalassemia were correctly coded in only 30.5% of 
hospitalizations overall; substantially higher in CA (56.2%) 
than in GA (22.4%).  Coding for Hb Sβ+ thalassemia was 
incorrect in 52.2% (26.3% in CA, 60.3% in GA), and 
indeterminate in 7.0% (6.6% in CA, 7.2% in GA) (Figure 2). 
Two percent of hospitalizations for individuals with SCD in 
California and 4% in Georgia did not contain an SCD ICD-9-
CM diagnosis code.  The lack of any SCD diagnosis code was 
higher for Hb Sβ+ thalassemia (10.3%) compared with Hb 
SC (4.7%) and SCA (2.3%).  
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In our cohort of hospitalizations for individuals with 
SCD from both California and Georgia, using Hb SS ICD-
9-CM codes only (282.61, 282.62) versus any SCD code to 
identify a pediatric patient with SCA improved the positive 
predictive value (PPV) from 84% (9,850/11,740) to 93% 
(7,750/8,306); however, in the adult population the PPV 
only slightly improved from 79% (12,229/15,435) to 81% 
(10,352/12,752) (Table 2).
Discussion
One of the most important distinctions to make, when 
treating patients with SCD or evaluating their health and 
healthcare utilization patterns, is between patients with SCA 
genotypes and patients with other forms of SCD, because 
patients with SCA are at a higher risk for many disease-
related complications and hospitalization14,26.  However, 
the use of ICD-9-CM codes for determining specific SCD 
genotypes is problematic for multiple reasons. First, although 
it is sometimes difficult to distinguish Hb SS from Hb Sβ0 
thalassemia based on results of hemoglobin electrophoresis 
or other non DNA tests, there is no single ICD-9-CM code 
for SCA, rather there are separate codes for “hemoglobin-SS 
disease with/without crisis” (282.61, 282.62) and “sickle-
cell thalassemia with/without crisis” (282.41, 282.42). 
Furthermore, the latter ICD-9-CM codes do not differentiate 
between Hb Sβ° thalassemia and Hb Sβ+ thalassemia, the 
former genotype causing SCA, while the latter does not. 
The difficulty in distinguishing between SCA genotypes, 
even with the presence of laboratory-based results, is the 
reason that the SCD surveillance data collected by Georgia 
and California, and used for the analyses presented here, 
utilized an SCA classification, rather than separate Hb SS and 
Hb Sβ0 thalassemia genotypes.   Moreover, the limitations 
of the ICD-9-CM codes for determining SCD genotypes 
were the reason that the SCD surveillance data collected on 
individuals without a newborn screening report or diagnosis 
from a hemoglobinopathy specialty treatment center did not 
contain genotype information and were, therefore, excluded 
from this analysis. 
In addition to the inherent limitations of the SCD ICD-9-
CM codes themselves, our study indicates that there is also 
misuse of these codes, as has been previously reported25. 
That study from a single pediatric emergency department 
noted that the accuracy of correctly identifying individuals 
with Hb SS was 87%, with sensitivity, specificity, and PPV 
of 87%, 79%, and 87% respectively. Our study showed the 
accuracy of identifying individuals with SCA in hospital 
discharge data was similar.  However the accuracy of ICD-
9-CM codes to identify other SCD genotypes was poor, 
especially for individuals with Hb SC; over 75% of their 
hospitalizations contained an ICD-9-CM code that did not 
match their true SCD genotype. For Hb Sβ+ thalassemia, 
accuracy was also low (69%).  This miscoding may be, 
in part, because some healthcare providers and coders 
do not appreciate the differences among SCD genotypes, 
leading to the use of Hb SS codes for non-Hb SS genotypes. 
While these analyses were based on ICD-9-CM codes, it is 
important to recognize that the ICD-10-CM codes for SCD 
that are now being used have similar limitations.
The lack of SCA ICD-9-CM codes, ambiguous codes for Hb 
Sβ0 thalassemia vs Hb Sβ+ thalassemia, and the high rates of 
mismatch between true SCD genotype and the SCD ICD-9-CM 
codes in hospital discharge data may lead to the erroneous 
interpretation of such data and mistaken conclusions. 
Using hospital discharge data to analyze hospital admission 
and/or readmission rates, the rate of a particular surgical 
procedure, or adherence to recommended therapy by 
genotype could incorrectly classify up to 15% of individuals 
with SCA, three-fourths of those with Hb SC, and over two-
thirds of those with Hb Sβ+ thalassemia. Errors such as these 
could lead to incorrect understanding of the disease and 
adherence to recommended management and treatment. 
Our results suggest that caution should be exercised when 
interpreting research that relies solely on hospital discharge 
data to identify and determine the genotype of individuals 
with SCD.  
The results presented here further suggest that using 
Table 2: Positive predictive value of using Hemoglobin SS ICD-9-CM hospital discharge codes (282.61 or 282.62) to identify individuals 
with sickle cell anemia, California and Georgia, 2004-2008
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only Hb SS ICD-9-CM codes to identify individuals with SCA 
improves the genotypic accuracy of the resulting sample for 
pediatric patients when compared to using all SCD ICD-9-
CM codes, but does little to improve identification of adults 
with SCA.  These results are due, in part, to the high rates 
of miscoding for non-SCA genotypes, as well as the higher 
rates of hospitalization in individuals with SCA (80% of the 
SCD hospitalizations in this analysis, but only 73% of the 
patients with a hospitalization and 64% of all identified 
individuals with SCD, regardless of hospitalization). 
A fundamental strength of this study is the identification 
of cohort members through population-based surveillance, 
rather than identification solely in administrative data or 
a SCD specialty clinic(s).  While the use of administrative 
data alone requires fewer resources, it is often incomplete 
and may suffer from suboptimal quality.  Data from SCD 
specialty clinics have higher quality and more complete 
reporting, but contain a limited number of cases and may 
not represent a population-based sample of all patients.
This analysis also has limitations.  It has a narrow 
focus on hospital discharge data, thus excluding the 
37.7% of patients with known SCD genotypes who were 
not hospitalized during the five year period.  Results 
from other commonly used administrative datasets, such 
as Medicaid or emergency department claims data, may 
show levels of congruence between true SCD genotype and 
ICD-9-CM genotype that vary from the results presented 
here.  Furthermore, this study did not include individuals 
with SCD for whom a laboratory-confirmed genotype was 
not available.  That is, the individuals who were neither 
born in California or Georgia during the years of active 
newborn screening nor receiving care from one of the 
participating clinics.  Finally, there were a large number 
of hospitalizations during this five-year study period that 
contained an SCD ICD-9-CM code, but were not linked to 
our cohort.
These findings underscore the need for surveillance 
systems that can accurately identify individuals living 
with SCD along with their correct genotype, track their 
health care utilization, and monitor their quality of care 
by measuring adherence to practice guidelines in ways 
that have the potential to reduce SCD associated morbidity 
and mortality and improve care.  Until a national registry 
or other data collection system is available for SCD in the 
US, researchers will be limited by the accuracy of ICD-9-
CM or, since late 2015, ICD-10-CM codes for determining 
SCD genotype.  Therefore, caution must be used when 
interpreting results and applying findings to the 
development of practice guidelines or recommendations 
for clinical care.  
Note
 This project was reviewed by CDC and was determined 
to be a non-research, public health practice activity. Both the 
California Committee for Protection of Human Subjects and 
the Georgia Public Health Department Institutional Review 
Board declared the project exempt from review as a public 
health surveillance effort; specialty hemoglobinopathy 
treatment center institutional review boards similarly 
exempted the project from review. State data requests were 
reviewed by the appropriate agency, assuring data privacy 
safeguards were in place.  The findings and conclusions in 
this report are those of the authors and do not necessarily 
represent the official position of the Centers for Disease 
Control and Prevention.
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